Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Gynecologic Cancers
Ovarian Cancer
Primary Peritoneal Cancer
18 Years and older, Female
QPT-ORE-005 (primary)
NCI-2020-08028
FLORA5
FLORA-5
GOG 3035
GOG-3035
Summary
Study to compare the safety and efficacy of oregovomab versus placebo, administered in
combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and
carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who
have undergone optimal debulking.
Objectives
Phase 3 double-blind, placebo-controlled, multi-center study to compare the safety and
efficacy of four administrations of oregovomab 2 mg IV versus placebo, administered in
combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and
carboplatin), for the treatment of subjects with newly diagnosed ovarian cancer who have
undergone optimal debulking surgery and are either pending initiation of chemotherapy (Cohort
1 - Primary Surgery) or resumption of another three cycles of chemotherapy, having already
completed three cycles of neoadjuvant chemotherapy (Cohort 2 - NACT + Interval Surgery).
For Cohort 1 - Primary Surgery, 372 subjects randomized in a 1:1 ratio (i.e., chemotherapy
with oregovomab or chemotherapy with placebo). For Cohort 2 - NACT + Interval Surgery, 230
subjects will be randomized in a 1:1 ratio (i.e., chemotherapy with oregovomab or
chemotherapy and placebo).
Eligibility
- Adults 18 years old or older.
- Newly diagnosed epithelial adenocarcinoma of ovarian, fallopian tube or peritoneal origin FIGO Stage III or IV disease.
- Histologic epithelial cell types: high grade serous adenocarcinoma, high grade endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise specified (N.O.S.).
- Completed debulking surgery (either primary debulking surgery or interval debulking surgery at the discretion of the investigator). Debulking surgery must be optimal, R1 or R0 (defined as R1, macroscopic no greater than 1 cm in diameter, or R0, microscopic or no evidence of tumor).
- Preoperative serum CA- 125 levels = 50 U/mL.
- Adequate bone marrow function:
- Absolute neutrophil count (ANC) greater than or equal to 1,500/µL
- Platelets greater than or equal to100,000/µL
- Hemoglobin greater than or equal to 8.0 g/dL (Note: Blood transfusion is permitted up to 48 hours before first dose of study treatment).
- Adequate liver function:
- Bilirubin < 1.5 times upper limit normal (ULN)
- Lactate Dehydrogenase (LDH), SGOT/AST and SGPT/ALT < 2.5 times ULN
- Albumin >3.5 g/dL
- Adequate renal function: a. Creatinine less than or equal to1.5 times ULN
- ECOG Performance Status of 0 or 1.
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.